About us
Firebrick Pharma was founded by Peter Molloy and Stephen Goodall (picture) in 2012 with the mission to develop a nasal spray based on povidone-iodine (PVP-I) for use as a treatment for the common cold.
Firebrick technology
and patents
Povidone-iodine (or PVP-I) is the active ingredient in Nasodine® Nasal Spray and Firebrick’s other Nasodine brand products in development. Firebrick scientists are experts in the field of PVP-I and have filed numerous patents.
CEO presentations
and interviews
Gain important insights into our company's growth strategy and financial performance via our CEO Presentations and interviews.
